Tag: core

Selangor, Malaysia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Empro Group Inc. (the “Company” or “EMPG”), a rising beauty and personal care brand headquartered in Malaysia, today announced that it closed the sales of an additional 91,250 ordinary shares of the Company, representing the exercise of the remaining portion of the underwriter’s over-allotment option granted in connection with the Company’s initial public offering (the “IPO”, and together with such over-allotment closing, the “Offering”), at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised gross proceeds of $365,000 in addition to the previously announced IPO gross proceeds of approximately $5,500,000 and the previously announced gross proceeds of $460,000 arising from the partial exercise by the underwriter of its over-allotment option that closed on July 30, 2025, for aggregate gross of proceeds of $6,325,000, before deducting underwriting discounts and other offering expenses.

With over $4 billion in net assets, the Global X Uranium ETF is the world’s preeminent ETF providing investors broad exposure to companies involved in uranium mining and the production of nuclear components

All amounts in U.S. dollars unless otherwise indicated

RACINE, Wis., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Outdoors Inc. (Nasdaq:JOUT), a leading global innovator of outdoor recreation equipment and technology, today announced operating results for the Company’s third fiscal quarter ending June 27, 2025.

LOUISVILLE, Ky., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the second quarter ended June 30, 2025, and increased Revenue and Adjusted EBITDA¹ guidance.

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”).